Tibotec, FDA Update Warning Label on HIV Drug's Risk of Severe Skin Reaction
August 27, 2009
Tibotec Therapeutics, a unit of Johnson & Johnson, "has strengthened a warning about serious skin reactions in patients treated with the company's HIV drug Intelence," the FDA and the company said on Wednesday, Reuters reports. Intelence has included a warning about the risk of severe skin reactions since its approval in Janurary 2008, according to Pamela Van Houten, a spokesperson for Tibotec (Richwine, 8/26).
"The skin condition called toxic epidermal necrolysis has killed one patient and injured another since Intelence was approved. ... Another patient taking the tablets reported a hypersensitivity reaction accompanied by liver failure, [Van Houten] said," Bloomberg reports (Larkin, 8/26). According to the Associated Press/Los Angeles Times, "The new label warns physicians to discontinue use of the drug if patients develop rash, fever, fatigue and other signs of an adverse reaction" (8/26).
Information for Health Care Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Health Care Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC)
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily U.S. HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.